Literature DB >> 22617813

Lung cancer screening: making the transition from research to clinical practice.

Horiana B Grosu1, George A Eapen, Carlos A Jimenez, Rodolfo C Morice, David Ost.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to examine the literature on lung cancer screening with an emphasis on the prevalence of cancer in screen-detected nodules. On the basis of the evidence, we will then develop a practical approach to screen-detected lung nodules. RECENT
FINDINGS: The first large randomized controlled trial using low-dose computed tomography (LDCT) found that persons undergoing three annual screening examinations with LDCT had a 20% relative reduction in lung cancer mortality as compared with those screened with annual chest X-rays. The probability of cancer in screen-detected nodules depends on their size and whether the nodules are detected on prevalence or incidence screens. The probability of cancer in screen-detected nodules ranges from 2.4 to 5.2%. Management strategies for screen-detected nodules that have been used successfully include careful observation using serial CT imaging, CT-guided fine needle biopsy, and surgery in carefully selected cases. The most frequently used strategies involve serial CT imaging and CT-guided biopsy for larger nodules and those that demonstrate growth on follow-up.
SUMMARY: There is now evidence that LDCT in carefully selected high-risk populations can lead to better outcomes but the cost effectiveness of mass screening with LDCT is still unknown. Only patients at high risk for cancer should be screened.

Entities:  

Mesh:

Year:  2012        PMID: 22617813     DOI: 10.1097/MCP.0b013e3283548139

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  4 in total

1.  Quality gaps and comparative effectiveness in lung cancer staging: the impact of test sequencing on outcomes.

Authors:  Francisco A Almeida; Roberto F Casal; Carlos A Jimenez; George A Eapen; Mateen Uzbeck; Mona Sarkiss; David Rice; Rodolfo C Morice; David E Ost
Journal:  Chest       Date:  2013-12       Impact factor: 9.410

2.  Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2-3 After Progression of Second-Line or Later-Line Treatment.

Authors:  Xiao-Hong Xie; Fei Wang; Xin-Qing Lin; Yin-Yin Qin; Zhan-Hong Xie; Jie-Xia Zhang; Ming Ouyang; Cheng-Zhi Zhou
Journal:  Cancer Manag Res       Date:  2020-12-10       Impact factor: 3.989

3.  Is chest X-ray screening for lung cancer in smokers cost-effective? Evidence from a population-based study in Italy.

Authors:  Paolo Pertile; Albino Poli; Lorenzo Dominioni; Nicola Rotolo; Elisa Nardecchia; Massimo Castiglioni; Massimo Paolucci; William Mantovani; Andrea Imperatori
Journal:  Cost Eff Resour Alloc       Date:  2015-09-12

Review 4.  Opportunities to address lung cancer disparities among African Americans.

Authors:  Steven S Coughlin; Patricia Matthews-Juarez; Paul D Juarez; Courtnee E Melton; Mario King
Journal:  Cancer Med       Date:  2014-09-14       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.